Search the Newsreel

Rock Springs Capital Management LP Raises Stock Holdings in Bicara Therapeutics Inc. $BCAX

Rock Springs Capital Management LP increased its stake in Bicara Therapeutics Inc. by 14% in the first quarter, now holding 489,095 shares valued at $9.7 million. Despite the company missing its Q1 earnings estimates with a loss of $0.93 per share, Bicara's stock opened …

Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?

Bicara Therapeutics (BCAX) has appointed Jeremy Bender and Christy Oliger to its Board of Directors, bringing extensive oncology drug development and commercialization experience. These appointments could significantly influence the company's late-stage strategy for its lead asset, FICERA, particularly concerning its FORTIFI HN01 trial and …

Bicara Therapeutics (BCAX) director reports initial Form 3 filing

Bicara Therapeutics Inc. director Christy J. Oliger has filed an initial Form 3, an Initial Statement of Beneficial Ownership. The filing indicates no current equity or derivative security holdings and no reported transactions, with a reference to a Power of Attorney document. This report …

Bicara Therapeutics grants options to director | BCAX Insider Trading

Bicara Therapeutics (BCAX) has granted its director, Jeremy Bender, 38,950 stock options. These options have an exercise price of $26.88 per share and expire on July 28, 2036. The shares will vest in stages, with one-third vesting on July 28, 2027, and the remainder …

Bicara Therapeutics (BCAX) awards 38,950 stock options to board director

Bicara Therapeutics (BCAX) director Christy J. Oliger was granted 38,950 stock options with an exercise price of $26.88 per share, expiring on July 28, 2036. The options will vest one-third on July 28, 2027, with the remainder vesting in 24 equal monthly installments, contingent …

Bicara Therapeutics Inc. (BCAX) director Jeremy Bender files ownership report

Bicara Therapeutics Inc. director Jeremy Bender has filed an initial statement of beneficial ownership (Form 3), indicating his role as a director. The filing reports no transactions or specific equity holdings for Bender and refers to an accompanying Exhibit 24 - Power of Attorney. …

Bicara Therapeutics Oliger Recently Served as Senior Vice Pres of the Oncology Business Unit at Genentech >BCAX

Bicara Therapeutics has appointed Natalie R. Oliger, an executive with significant oncology experience from Genentech, to its Board of Directors. Her appointment is expected to provide valuable strategic insights as Bicara advances its pipeline.

Bicara Therapeutics adds two directors to board

Bicara Therapeutics Inc. (NASDAQ:BCAX) has announced the appointment of Jeremy Bender and Christy Oliger to its board of directors, expanding its leadership team. Jeremy Bender brings over 20 years of experience in biotechnology, including leading Day One Biopharmaceuticals through its acquisition. Christy Oliger adds …

Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors

Bicara Therapeutics has announced the appointments of Jeremy Bender and Christy Oliger to its Board of Directors. This news was reported by Refinitiv and is available on TradingView. The article indicates that full access to the content is available on TradingView, along with other …

Bicara Therapeutics Inc (BCAX) Earnings Date & Reports & Earnings News

BlackRock (BCAX holder) discloses 5.4% Bicara Therapeutics stake on Schedule 13G

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership stake of 5.4% in Bicara Therapeutics Inc. (BCAX). As of June 30, 2026, BlackRock beneficially owned 3,536,271 shares of Bicara's common stock, holding sole voting power over 3,464,981 shares and sole dispositive power …

Bicara Therapeutics Inc (BCAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Bicara Therapeutics Inc (BCAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bicara Therapeutics Inc (BCAX), detailing its performance based on various indicators and moving averages. It offers insights into the stock's current technical status, including buy/sell signals from MACD, RSI, and different moving averages. The analysis concludes with …

Bicara Therapeutics Inc (BCAX) Cash Flow

This article provides a detailed cash flow statement for Bicara Therapeutics Inc (BCAX), including operating, investing, and financing cash flows presented quarterly and annually. It also includes an FAQ section explaining key cash flow concepts and specific figures for BCAX, such as operating cash …

BCAX|Bicara Therapeutics Inc|Price:27.020|Chg%:-0.710

This article provides a detailed financial overview of Bicara Therapeutics Inc (BCAX), including its current stock price, market capitalization, key financial figures, and recent performance. It also includes analyst ratings, indicators, and company information, emphasizing its focus on developing bifunctional therapies for solid tumors. …

Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average "Moderate Buy" rating from fifteen analysts, with a consensus 12-month price target of $30.27. Despite the stock trading near its 1-year high, the company reported an EPS loss that missed estimates, and internal insider selling has …

Bicara Therapeutics (BCAX) Proxy filing Summary

Bicara Therapeutics (BCAX) will hold its annual meeting virtually on June 9, 2026, where shareholders will vote on the election of two Class II directors and the ratification of KPMG LLP as the independent auditor for 2026. The board recommends voting in favor of …

Bicara Therapeutics (BCAX) Corporate presentation Summary

Bicara Therapeutics (BCAX) presented a corporate summary focusing on its lead candidate, ficerafusp alfa (FICERA), a bifunctional antibody targeting EGFR and TGF-β for HPV-negative head and neck squamous cell carcinoma (HNSCC). The company highlighted FICERA's potential for blockbuster status, given its strong clinical efficacy—demonstrating …

Bicara Therapeutics (BCAX) Study update Summary

Bicara Therapeutics (BCAX) released a study update on May 22, 2026, detailing the efficacy and safety of Ficera (ficerafusp alfa) plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The phase 1/1b expansion cohorts showed nearly double the three-year overall …

Bicara Therapeutics (BCAX) Q1 2026 earnings summary

Bicara Therapeutics (BCAX) reported its Q1 2026 earnings, highlighting progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, with enrollment expected by year-end 2026 and interim analysis in mid-2027. The company's cash reserves increased to $539.8M following a $161.8M public offering, extending its cash …

Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com

This article reports on a Form 4 filing for Bicara Therapeutics Inc. on July 14, 2026. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article provides only this headline information and includes no further …

BCAX Forecast — Price Target — Prediction for 2027

Bicara (BCAX) Q4 2025 Earnings Transcript

Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...

Earnings call transcript: Bicara Therapeutics Q1 2026 sees stock dip after earnings miss

Bicara Therapeutics Q1 2026 Loss Widens 40.9% Beyond Estimates

A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics Inc. (BCAX) Live Share Price, Invest From India